GlassScriptPhysician profile
Melanie Choi
NPI 1316566094
$6,784.02
in general payments reported to CMS, 2019-2025
22 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,121 · 2024: $3,045 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,688 · Education: $95.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,688.14 |
| Education | $95.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,399.72 | 2023-2025 | |
| Abbvie INC. | $1,308.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $821.49 | 2024-2025 | Dupixent |
| Ucb, INC. | $488.63 | 2023-2025 | Bimzelx |
| Incyte Corporation | $434.39 | 2023-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $369.58 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $314.33 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $308.41 | 2024-2025 | Tremfya |
| Pfizer INC. | $265.38 | 2023-2025 | |
| Lilly USA, LLC | $244.45 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $153.70 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Novartis Pharmaceuticals Corporation | $128.66 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $120.49 | 2024-2025 | |
| Leo Pharma INC. | $94.86 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $91.99 | 2023-2024 | Sotyktu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $85.10 | 2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $52.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.44 | 2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $24.87 | 2024 | Ycanth |
| Cipher Pharmaceuticals US LLC | $21.64 | 2025 | Natroba, Spinosad |
| Botanix Sb INC | $20.13 | 2025 | Sofdra |
| Organon LLC | $4.79 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.